Ivonescimab Looking to Rival Merck’s Keytruda in NSCLC with Phase III Trial Enrollment Complete

Summit Therapeutics Inc. has announced completion of enrollment for its HARMONi clinical trial evaluating ivonescimab in combination with platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI).